Jci_page_head_homepage_01 Jci_page_head_homepage_02
Seiji Kawamoto, Ali Yalcindag, Dhafer Laouini, Scott Brodeur, Paul Bryce, Bao Lu, Alison A. Humbles, Hans Oettgen, Craig Gerard, Raif S. Geha
Published in Volume 114, Issue 3
J Clin Invest. 2004; 114(3):399–407 doi:10.1172/JCI19082
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 8

(A) Effect of pretreatment of BALB/C splenic DCs with C3a on their ability to support cytokine production by DO11.10 TCR-OVA transgenic T cells in response to OVA peptide. (B) Effect of supernatants of splenic DCs treated with C3a, then depleted of C3a, on cytokine production by DO11.10 TCR-OVA transgenic T cells in response to OVA peptide presented by fresh DCs. Columns and error bars represent mean ± SEM of three experiments. *P < 0.05. (C) Dose-response analysis of the effect of supernatants from C3a-stimulated DCs on IL-4 secretion. Sup, supernatant.